Report Overview

Europe's prothrombin complex concentrate market is growing owing to less administration time and several advantages over alternative anticoagulation-reversal therapies like Fresh Frozen Plasma. Moreover, an increase in warfarin-associated bleeding disorders, the frequency of coagulation factor disorders, and people's rising income levels are also propelling the Europe Prothrombin Complex Concentrate Market.

Europe Prothrombin Complex Concentrate Market - Industry Trends & Forecast Report 2028

The Europe Prothrombin Complex Concentrate market was worth USD 197.1 million in 2021 and is projected to reach USD 409.5 million by 2028, exhibiting a CAGR of 11.2% during the forecast period. The rapid expansion of the market is predominantly expanding due to factors like less time needed for administration and several advantages over other alternative anticoagulation-reversal therapies like Fresh Frozen Plasma. Moreover, an increase in warfarin-associated bleeding disorders, the frequency of coagulation factor disorders, and people's rising income levels are also propelling the Europe Prothrombin Complex Concentrate Market.

Prothrombin Complex Concentrate Market - Overview

Blood coagulation factors II, IX, and X are the drug prothrombin complex concentrate (PCC) components. Patients with inherited or acquired deficits can use them to replace factor II or X. After factor XI and antithrombin have been removed, huge plasma pools are subjected to ion exchange chromatography to produce prothrombin complex concentrate. Prothrombin complex concentrate can be used to prevent bleeding in haemophilia B due to the removal of factor XI. Prothrombin complex concentrates are emergency medications intended to treat bleeding episodes related to hemophilia B, congenital deficits of other vitamin K-dependent clotting diseases, or severe liver disease.

Europe Prothrombin Complex Concentrate (PCC) Market Forecast and Trends

Growth Drivers

PCC Advantages Over Other Anticoagulation-Reversal Therapies to Drive Growth

PCC is frequently used in urgent warfarin reversals as it offers a number of advantages over other anticoagulation-reversal medications, including FFP (Fresh Frozen Plasma), Vitamin K1, and others. The main benefit of PCC is that it does not require blood type matching or thawing, which are necessary in the case of FFP, and thus it reduces the overall administration time. Additionally, due to the inclusion of several clotting factors, PCC products have a shorter penetration time and greater efficiency. As a result, fewer quantities are needed as compared to conventional anticoagulation-reversal therapies. A few governmental organizations, like the Italian Federation of Anticoagulation Clinics, The American College of Chest Physicians (ACCP), and others, advocate using PCC over FFP in life-threatening bleeding due to these benefits. For its effectiveness in reversing Vitamin K antagonists, PCC is chosen by medical experts, which is a major driver of the PCC market's anticipated growth.

Increased Uptake of Vitamin K Antagonists Will Drive the Market

The introduction of several Vitamin K antagonist medicines, particularly warfarin, is expected to increase PCC use. Warfarin prescriptions are rising due to the relatively widespread usage of warfarin as anticoagulants. Prothrombin complex concentrate is the most chosen treatment for Vitamin K medication's urgent need for reversal due to its quick action and low risk of viral transmission, but it is also linked to adverse drug events that necessitate immediate intervention. Thus, it is anticipated that rising warfarin prescriptions will support PCC market expansion during the course of the projection year. Additionally, it is projected that favorable government recommendations and guidelines for using factor IX complex during urgent warfarin reversal will benefit the industry.

Restraints

High PCC Treatment Costs Will Limit Market Expansion

Prothrombin complex concentrate has several benefits; however, certain factors prevent the industry from expanding. According to the World Federation of Hemophilia, its high price is one of these factors. Hemophilia medicines, such as factor concentrates, are among the top 10 most expensive therapeutics to be purchased. For instance, whereas Beriplex costs between US$ 155 and US$ 626.0 in the U.K, the 4-factor PCC Octaplex (500 iu/vial) costs about US$ 300.7 per vial. On the other hand, freshly frozen plasma therapy costs roughly US$ 34.2 per dosage. As a result, the high cost of PCC is anticipated to hamper the market growth in the coming years.

Impact of COVID-19 on Europe's Prothrombin Complex Concentrate Market

The COVID-19 outbreak has not significantly impacted the expansion of the prothrombin complex concentrate market. For instance, according to the company's quarterly report, the COVID19 pandemic had no major revenue impact on CSL Limited, one of the market's leading companies. In actuality, sales of the company's specialty products increased by a typical 10%. Sales for perioperative bleeding increased by 10%, mostly due to the high demand for Beriplex and the firm's fibrinogen concentrate products used to treat acute bleeding. Due to the cancellation of elective surgeries, the need for blood and blood products declined during the pandemic. However, despite the implementation of measures like social distancing and total or partial lockdowns of cities, provinces, or nations, the demand for PCCs has remained consistent as a result of their application in emergency warfarin-reversal scenarios. A significant increase in production and supply of factor IX complex was noted, particularly during the COVID-19 pandemic when hospitals began making large-scale purchases of vital medications, significantly boosting the prothrombin complex concentrate market.

Europe Prothrombin Complex Concentrate Market - By Type

Based on Type, the market segment is divided into 3-factor and 4-factor. In terms of revenue, the 4-factor PCC category led the Europe PCC market. The introduction of activated PCC products by major manufacturers and the rising off-label use of 4-factor PCC, including Cofact & Octaplex in Europe, were the significant drivers of this market's dominance in 2021. For instance, 1-2% of people in Europe are currently using oral vitamin K antagonists like warfarin, which puts them at an elevated risk of bleeding of 1.0 to 15.0%, according to a springer study. However, due to their lower cost when compared to 4-factor PCC, 3-factor PCC is preferred in Europe's price-sensitive nations, which is expected to spur the segment's growth over the forecast period. In addition, active government support to reduce the adverse effects linked to warfarin is projected to improve the market. As haemophilia becomes more common, the 3-factor market is expected to proliferate.

Europe Prothrombin Complex Concentrate Market - By End User

The market is divided into hospitals, ambulatory services, and others based on end-users. In terms of revenue, hospitals and ambulatory surgery centers held the lion's share, and it is anticipated that they would maintain their dominance throughout the forecast year. The leading position of the hospitals & ambulatory surgical centers segment during the forecast period is primarily attributable to favorable reimbursement policies for treatments for life-threatening rare congenital bleeding disorders and improved distribution of PCC products in hospital pharmacies. The "others" category includes clinics, doctor's offices, urgent care facilities, and emergency rooms. By 2028, the segment's growth is projected to be driven by an increase in trauma cases, an increase in the frequency of car accidents, and a rise in the usage of urgent care facilities as a result of better facilities.

Europe Prothrombin Complex Concentrate Market - Country Insights

Based on country, the Europe prothrombin complex concentrate market is divided into Germany, the United Kingdom, Italy, France, Spain, The Netherlands, Belgium, Russia, Poland, Portugal, Austria, and the Rest of Europe. Due to a large patient pool with congenital factor IX deficiency, Germany and France are predicted to be the leading countries in the Europe PCC market. On the other side, the U.K. is anticipated to expand at the highest pace during the projected period since haemophilia B is becoming more common in the country. According to projections, this will increase the country's adoption of PCC. The large demand for the Uman Complex D.I., a 3-factor PCC by Kendrion, in Italy, the rising prevalence of bleeding diseases, and the strong presence of major PCC producers all contribute to the likelihood that France and Italy will develop at a sustainable rate.

Competitive Landscape

Key players operating in the Europe prothrombin complex concentrate market are CSL Behring GmbH, OCTA Pharma AG, Kedrion S.P.A., Takeda Pharmaceuticals, China Biologic Products, Sanquin, Grifols S.A, Biotest, Abeona Therapeutics, Insud Pharma and other prominent players.

The existence of a limited number of prominent players, mostly pharmaceutical giants in Europe, has a significant impact on the prothrombin complex concentrate market's competitive dynamics. These businesses are concentrating on launching new PCC products to meet the increasing regional need for effective treatments for bleeding disorders.

Recent Development

• In April 2022, Grifols completed the acquisitions of Biotest AG, a European healthcare company specializing in innovative hematology and clinical immunology.
• In April 2021, Octapharma AG conducted study research. The results pointed out the feasibility and possible benefits of a larger randomized trial and suggested that 4-Factor PCC may be a suitable substitute for Frozen Plasma in cardiac surgery.

Scope of the Report

Attributes	Details
Years Considered	Historical data – 2018-2021
	Base Year – 2021
	Estimated Year - 2022
	Forecast – 2022 – 2028
Facts Covered	Revenue in USD Million
Market Coverage	Germany, United Kingdom, Italy, France, Spain, The Netherlands, Belgium, Russia, Poland, Portugal, Austria, and the Rest of Europe
Product Service/Segmentation	By Type, By End User, By Application, By Country
Key Players	CSL Behring GmbH, OCTA Pharma AG, Kedrion S.P.A., Takeda Pharmaceuticals, China Biologic Products, Sanquin, Grifols S.A, Biotest, Abeona Therapeutics, Insud Pharma, and Other Prominent Players.

 

By Type

• 3-Factor
• 4-Factor

By End User

• Hospital
• Ambulatory Services
• Others

By Application

• Acquired Coagulation Factor Deficiency
• Congenital Coagulation Factor Deficiency
• Others

By Country

• Germany
• United Kingdom
• Italy
• France
• Spain
• The Netherlands
• Belgium
• Russia
• Poland
• Portugal
• Austria
• Rest of Europe

1. Research Framework
   1. Research Objective
   2. Product Overview
   3. Market Segmentation
2. Research Methodology
   1. Qualitative Research
      1. Primary & Secondary Research
   2. Quantitative Research
   3. Market Breakdown & Data Triangulation
      1. Secondary Research
      2. Primary Research
   4. Breakdown of Primary Research Respondents, By Region
   5. Assumption & Limitation
3. Executive Summary
4. Europe Prothrombin Complex Concentrate Market Insights
   1. Industry Value Chain Analysis
   2. DROC Analysis
      1. Growth Drivers
      2. Restraints
      3. Opportunities
      4. Challenges
   3. Technological Landscape/Recent Development
   4. Regulatory Framework
   5. Porter’s Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of New Entrants
      4. Threat of Substitutes
      5. Intensity of Rivalry
5. Europe Prothrombin Complex Concentrate Market Overview
   1. Market Size & Forecast by Value, 2018-2028
      1. By Value (USD Million)
   2. Market Share & Forecast
      1. By Type
         1. 3-Factor
         2. 4-Factor
      2. By End-User
         1. Hospital
         2. Ambulatory Services
         3. Others
      3. By Application
         1. Acquired Coagulation Factor Deficiency
         2. Congenital Coagulation Factor Deficiency
         3. Others
      4. By Country
         1. Germany
         2. United Kingdom
         3. Italy
         4. France
         5. Spain
         6. The Netherlands
         7. Belgium
         8. Russia
         9. Poland
         10. Portugal
         11. Austria
         12. Rest of Europe
6. Germany Prothrombin Complex Concentrate Market
   1. Market Size & Forecast by Value, 2018-2028
      1. By Value (USD Million)
   2. Market Share & Forecast
      1. By Type
      2. By End-User
      3. By Application
7. United Kingdom Prothrombin Complex Concentrate Market
   1. Market Size & Forecast by Value, 2018-2028
      1. By Value (USD Million)
   2. Market Share & Forecast
      1. By Type
      2. By End-User
      3. By Application
8. Italy Prothrombin Complex Concentrate Market
   1. Market Size & Forecast by Value, 2018-2028
      1. By Value (USD Million)
   2. Market Share & Forecast
      1. By Type
      2. By End-User
      3. By Application
9. France Prothrombin Complex Concentrate Market
   1. Market Size & Forecast by Value, 2018-2028
      1. By Value (USD Million)
   2. Market Share & Forecast
      1. By Type
      2. By End-User
      3. By Application
10. Spain Prothrombin Complex Concentrate Market
    1. Market Size & Forecast by Value, 2018-2028
       1. By Value (USD Million)
    2. Market Share & Forecast
       1. By Type
       2. By End-User
       3. By Application
11. The Netherlands Prothrombin Complex Concentrate Market
    1. Market Size & Forecast by Value, 2018-2028
       1. By Value (USD Million)
    2. Market Share & Forecast
       1. By Type
       2. By End-User
       3. By Application
12. Belgium Prothrombin Complex Concentrate Market
    1. Market Size & Forecast by Value, 2018-2028
       1. By Value (USD Million)
    2. Market Share & Forecast
       1. By Type
       2. By End-User
       3. By Application
13. Russia Prothrombin Complex Concentrate Market
    1. Market Size & Forecast by Value, 2018-2028
       1. By Value (USD Million)
    2. Market Share & Forecast
       1. By Type
       2. By End-User
       3. By Application
14. Poland Prothrombin Complex Concentrate Market
    1. Market Size & Forecast by Value, 2018-2028
       1. By Value (USD Million)
    2. Market Share & Forecast
       1. By Type
       2. By End-User
       3. By Application
15. Portugal Prothrombin Complex Concentrate Market
    1. Market Size & Forecast by Value, 2018-2028
       1. By Value (USD Million)
    2. Market Share & Forecast
       1. By Type
       2. By End-User
       3. By Application
16. Austria Prothrombin Complex Concentrate Market
    1. Market Size & Forecast by Value, 2018-2028
       1. By Value (USD Million)
    2. Market Share & Forecast
       1. By Type
       2. By End-User
       3. By Application
17. Rest of the Europe Prothrombin Complex Concentrate Market
    1. Market Size & Forecast by Value, 2018-2028
       1. By Value (USD Million)
    2. Market Share & Forecast
       1. By Type
       2. By End-User
       3. By Application
18. Competitive Landscape
    1. List of Key Players and Their Offerings
    2. Market Share Analysis, 2021
    3. Competitive Benchmarking, By Operating Parameters
    4. Key Strategic Development (Mergers, Acquisitions, Partnerships, etc.)
19. Impact of COVID-19 on Europe Prothrombin Complex Concentrate Market
20. Company Profile (Company Overview, Financial Matrix, Competitive landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook)
    1. CSL Behring GmbH
    2. OCTA Pharma AG
    3. Kedrion S.P.A.
    4. Takeda Pharmaceuticals
    5. China Biologic Products
    6. Sanquin
    7. Grifols S.A
    8. Biotest
    9. Abeona Therapeutics
    10. Insud Pharma
    11. Other Prominent Players
21. Key Strategic Recommendations

 

Note: Financial in information in case of non-listed companies will be provided as per availability

The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable

 

List of Figures

 

Figure 1: Europe Prothrombin Complex Concentrate Market Segmentation

Figure 2: Europe Prothrombin Complex Concentrate Market Industry Value Chain Analysis

Figure 3: Europe Prothrombin Complex Concentrate Market Size, By Value (USD Million), 2018-2028

Figure 4: Europe Prothrombin Complex Concentrate Market Share (%), By Type, By Value, 2018-2028

Figure 5: Europe Prothrombin Complex Concentrate Market Share (%), By End-User, By Value, 2018-2028

Figure 6: Europe Prothrombin Complex Concentrate Market Share (%), By Application, By Value, 2018-2028

Figure 7: Europe Prothrombin Complex Concentrate Market Share (%), By Country, By Value, 2018-2028

Figure 8: Germany Prothrombin Complex Concentrate Market Size, By Value (USD Million), 2018-2028

Figure 9: Germany Prothrombin Complex Concentrate Market Share (%), By Type, By Value, 2018-2028

Figure 10: Germany Prothrombin Complex Concentrate Market Share (%), By End-User, By Value, 2018-2028

Figure 11: Germany Prothrombin Complex Concentrate Market Share (%), By Application, By Value, 2018-2028

Figure 12: United Kingdom Prothrombin Complex Concentrate Market Size, By Value (USD Million), 2018-2028

Figure 13: United Kingdom Prothrombin Complex Concentrate Market Share (%), By Type, By Value, 2018-2028

Figure 14: United Kingdom Prothrombin Complex Concentrate Market Share (%), By End-User, By Value, 2018-2028

Figure 15: United Kingdom Prothrombin Complex Concentrate Market Share (%), By Application, By Value, 2018-2028

Figure 16: Italy Prothrombin Complex Concentrate Market Size, By Value (USD Million), 2018-2028

Figure 17: Italy Prothrombin Complex Concentrate Market Share (%), By Type, By Value, 2018-2028

Figure 18: Italy Prothrombin Complex Concentrate Market Share (%), By End-User, By Value, 2018-2028

Figure 19: Italy Prothrombin Complex Concentrate Market Share (%), By Application, By Value, 2018-2028

Figure 20: France Prothrombin Complex Concentrate Market Size, By Value (USD Million), 2018-2028

Figure 21: France Prothrombin Complex Concentrate Market Share (%), By Type, By Value, 2018-2028

Figure 22: France Prothrombin Complex Concentrate Market Share (%), By End-User, By Value, 2018-2028

Figure 23: France Prothrombin Complex Concentrate Market Share (%), By Application, By Value, 2018-2028

Figure 24: Spain Prothrombin Complex Concentrate Market Size, By Value (USD Million), 2018-2028

Figure 25: Spain Prothrombin Complex Concentrate Market Share (%), By Type, By Value, 2018-2028

Figure 26: Spain Prothrombin Complex Concentrate Market Share (%), By End-User, By Value, 2018-2028

Figure 27: Spain Prothrombin Complex Concentrate Market Share (%), By Application, By Value, 2018-2028

Figure 28: The Netherlands Prothrombin Complex Concentrate Market Size, By Value (USD Million), 2018-2028

Figure 29: The Netherlands Prothrombin Complex Concentrate Market Share (%), By Type, By Value, 2018-2028

Figure 30: The Netherlands Prothrombin Complex Concentrate Market Share (%), By End-User, By Value, 2018-2028

Figure 31: The Netherlands Prothrombin Complex Concentrate Market Share (%), By Application, By Value, 2018-2028

Figure 32: Belgium Prothrombin Complex Concentrate Market Size, By Value (USD Million), 2018-2028

Figure 33: Belgium Prothrombin Complex Concentrate Market Share (%), By Type, By Value, 2018-2028

Figure 34: Belgium Prothrombin Complex Concentrate Market Share (%), By End-User, By Value, 2018-2028

Figure 35: Belgium Prothrombin Complex Concentrate Market Share (%), By Application, By Value, 2018-2028

Figure 36: Russia Prothrombin Complex Concentrate Market Size, By Value (USD Million), 2018-2028

Figure 37: Russia Prothrombin Complex Concentrate Market Share (%), By Type, By Value, 2018-2028

Figure 38: Russia Prothrombin Complex Concentrate Market Share (%), By End-User, By Value, 2018-2028

Figure 39: Russia Prothrombin Complex Concentrate Market Share (%), By Application, By Value, 2018-2028

Figure 40: Poland Prothrombin Complex Concentrate Market Size, By Value (USD Million), 2018-2028

Figure 41: Poland Prothrombin Complex Concentrate Market Share (%), By Type, By Value, 2018-2028

Figure 42: Poland Prothrombin Complex Concentrate Market Share (%), By End-User, By Value, 2018-2028

Figure 43: Poland Prothrombin Complex Concentrate Market Share (%), By Application, By Value, 2018-2028

Figure 44: Portugal Prothrombin Complex Concentrate Market Size, By Value (USD Million), 2018-2028

Figure 45: Portugal Prothrombin Complex Concentrate Market Share (%), By Type, By Value, 2018-2028

Figure 46: Portugal Prothrombin Complex Concentrate Market Share (%), By End-User, By Value, 2018-2028

Figure 47: Portugal Prothrombin Complex Concentrate Market Share (%), By Application, By Value, 2018-2028

Figure 48: Austria Prothrombin Complex Concentrate Market Size, By Value (USD Million), 2018-2028

Figure 49: Austria Prothrombin Complex Concentrate Market Share (%), By Type, By Value, 2018-2028

Figure 50: Austria Prothrombin Complex Concentrate Market Share (%), By End-User, By Value, 2018-2028

Figure 51: Austria Prothrombin Complex Concentrate Market Share (%), By Application, By Value, 2018-2028

Figure 52: Rest of the Europe Prothrombin Complex Concentrate Market Size, By Value (USD Million), 2018-2028

Figure 53: Rest of the Europe Prothrombin Complex Concentrate Market Share (%), By Type, By Value, 2018-2028

Figure 54: Rest of the Europe Prothrombin Complex Concentrate Market Share (%), By End-User, By Value, 2018-2028

Figure 55: Rest of the Europe Prothrombin Complex Concentrate Market Share (%), By Application, By Value, 2018-2028

Figure 56: Europe Prothrombin Complex Concentrate Market Share Analysis, 2021

 

List of Tables 

       

Table 1: Europe Prothrombin Complex Concentrate Market Size, By Type, By Value (USD Million), 2018-2028

Table 2: Europe Prothrombin Complex Concentrate Market Size, By End-User, By Value (USD Million), 2018-2028

Table 3: Europe Prothrombin Complex Concentrate Market Size, By Application, By Value (USD Million), 2018-2028

Table 4: Europe Prothrombin Complex Concentrate Market Size. By Region, By Value (USD Million), 2018-2028

Table 5: Germany Prothrombin Complex Concentrate Market Size, By Type, By Value (USD Million), 2018-2028

Table 6: Germany Prothrombin Complex Concentrate Market Size, By End-User, By Value (USD Million), 2018-2028

Table 7: Germany Prothrombin Complex Concentrate Market Size, By Application, By Value (USD Million), 2018-2028

Table 8: United Kingdom Prothrombin Complex Concentrate Market Size, By Type, By Value (USD Million), 2018-2028

Table 9: United Kingdom Prothrombin Complex Concentrate Market Size, By End-User, By Value (USD Million), 2018-2028

Table 10: United Kingdom Prothrombin Complex Concentrate Market Size, By Application, By Value (USD Million), 2018-2028

Table 11: Italy Prothrombin Complex Concentrate Market Size, By Type, By Value (USD Million), 2018-2028

Table 12: Italy Prothrombin Complex Concentrate Market Size, By End-User, By Value (USD Million), 2018-2028

Table 13: Italy Prothrombin Complex Concentrate Market Size, By Application, By Value (USD Million), 2018-2028

Table 14: France Prothrombin Complex Concentrate Market Size, By Type, By Value (USD Million), 2018-2028

Table 15: France Prothrombin Complex Concentrate Market Size, By End-User, By Value (USD Million), 2018-2028

Table 16: France Prothrombin Complex Concentrate Market Size, By Application, By Value (USD Million), 2018-2028

Table 17: Spain Prothrombin Complex Concentrate Market Size, By Type, By Value (USD Million), 2018-2028

Table 18: Spain Prothrombin Complex Concentrate Market Size, By End-User, By Value (USD Million), 2018-2028

Table 19: Spain Prothrombin Complex Concentrate Market Size, By Application, By Value (USD Million), 2018-2028

Table 20: The Netherlands Prothrombin Complex Concentrate Market Size, By Type, By Value (USD Million), 2018-2028

Table 21: The Netherlands Prothrombin Complex Concentrate Market Size, By End-User, By Value (USD Million), 2018-2028

Table 22: The Netherlands Prothrombin Complex Concentrate Market Size, By Application, By Value (USD Million), 2018-2028

Table 23: Belgium Prothrombin Complex Concentrate Market Size, By Type, By Value (USD Million), 2018-2028

Table 24: Belgium Prothrombin Complex Concentrate Market Size, By End-User, By Value (USD Million), 2018-2028

Table 25: Belgium Prothrombin Complex Concentrate Market Size, By Application, By Value (USD Million), 2018-2028

Table 26: Russia Prothrombin Complex Concentrate Market Size, By Type, By Value (USD Million), 2018-2028

Table 27: Russia Prothrombin Complex Concentrate Market Size, By End-User, By Value (USD Million), 2018-2028

Table 28: Russia Prothrombin Complex Concentrate Market Size, By Application, By Value (USD Million), 2018-2028

Table 29: Poland Prothrombin Complex Concentrate Market Size, By Type, By Value (USD Million), 2018-2028

Table 30: Poland Prothrombin Complex Concentrate Market Size, By End-User, By Value (USD Million), 2018-2028

Table 31: Poland Prothrombin Complex Concentrate Market Size, By Application, By Value (USD Million), 2018-2028

Table 32: Portugal Prothrombin Complex Concentrate Market Size, By Type, By Value (USD Million), 2018-2028

Table 33: Portugal Prothrombin Complex Concentrate Market Size, By End-User, By Value (USD Million), 2018-2028

Table 34: Portugal Prothrombin Complex Concentrate Market Size, By Application, By Value (USD Million), 2018-2028

Table 35: Austria Prothrombin Complex Concentrate Market Size, By Type, By Value (USD Million), 2018-2028

Table 36: Austria Prothrombin Complex Concentrate Market Size, By End-User, By Value (USD Million), 2018-2028

Table 37: Austria Prothrombin Complex Concentrate Market Size, By Application, By Value (USD Million), 2018-2028

Table 38: Rest of the Europe Prothrombin Complex Concentrate Market Size, By Type, By Value (USD Million), 2018-2028

Table 39: Rest of the Europe Prothrombin Complex Concentrate Market Size, By End-User, By Value (USD Million), 2018-2028

Table 40: Rest of the Europe Prothrombin Complex Concentrate Market Size, By Application, By Value (USD Million), 2018-2028

Table 41: List of Key Players and Their Offerings

Table 42: Competitive Benchmarking, by Operating Parameters

Table 43:       CSL Behring GmbH Company Overview                       

Table 44:       CSL Behring GmbH Financial Overview     

Table 45:       OCTA Pharma AG Company Overview                                   

Table 46:       OCTA Pharma AG Financial Overview                                    

Table 47:       Kedrion S.P.A. Company Overview                              

Table 48:       Kedrion S.P.A. Financial Overview                              

Table 49:       Takeda Pharmaceuticals Company Overview                                    

Table 50:       Takeda Pharmaceuticals Financial Overview                                     

Table 51:       China Biologic Products Company Overview                                     

Table 52:       China Biologic Products Financial Overview                            

Table 53:       Sanquin Company Overview                            

Table 54:       Sanquin Financial Overview                             

Table 55:       Grifols S.A company Overview                          

Table 56:       Grifols S.A Financial Overview

Table 57:       Biotest Company Overview                              

Table 58:       Biotest Financial Overview                               

Table 59:       Abeona Therapeutics Company Overview                              

Table 60:       Abeona Therapeutics Financial Overview                               

Table 61:       Insud Pharma Company Overview                     

Table 62:       Insud Pharma Financial Overview